MOUNTAIN VIEW, Calif., Jan. 4 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held, product based biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will present a company update at the 25th Annual JP Morgan Healthcare Conference which is being held January 8 - 11, 2007 at the Westin St. Francis Hotel in San Francisco. Timothy S. Nelson, MAP Pharmaceuticals' President and CEO, will make the company's presentation on Wednesday, January 10, 2007, at 10:00 am (PST) in the Elizabethan C/D Conference Room.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held, product based biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. The Company has two Phase 2 clinical development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of an inhaled ergot alkaloid for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

SOURCE MAP Pharmaceuticals, Inc.